Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adult, Advairmay, andArzerra, andBactroban, andCoreg, andDuac, andEno, andEpivir, andLovaza, andRequip, andRibena, andSelzentry, animal, antitrust, API, asymptomatic, bilateral, bipolar, BothHycamtin, category, CCM, certainty, compliant, content, CPI, Daiichi, deliberately, discretion, discretionary, doctor, EMAP, embed, equating, ExcludingCervarix, fromAugmentin, geography, GMP, HPV, imperative, inAquafresh, inAvodart, incident, includingAbreva, includingPanadol, incomplete, inJalyn, innate, intensify, JV, lawfully, lersivirine, lifecycle, Lip, misaligned, misuse, multinational, noncompliance, ofAdvair, ofAvodart, ofBenlysta, ofBonviva, ofCervarix, ofDermovate, ofLamictal, ofLucozade, ofPromacta, ofToctino, onFebruary, pursuit, reappointment, ReportedBenlysta, retrieval, RPI, Sankyo, sarcoma, signal, Skin, spirit, stake, storage, storm, StrongBactroban, strongCervarix, suboptimal, substitution, surveillance, susceptible, tenure, theAdvair, TheAvodart, theBenlysta, theLamictal, TheMaxinutrition, Theravance, TheSensodyne, theVesicare, toArixtra, toCombivir, toLamictal, toSeretide, unacceptable, unresolved, weakening, welfare, XR
Removed:
create, Crispin, delegate, diversified, exemption, Mellon
Filing tables
Filing exhibits
GSK similar filings
Filing view
External links
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (Nos. 333-172621, 333-172621-01 and 333-172621-02) of GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc., and in the Registration Statements on Form S-8 (Nos. 333-13022, 333-88966, 333-100388 and 333-162702) of GlaxoSmithKline plc of our report dated 28 February 2014, relating to the financial statements and the effectiveness of internal control over financial reporting of GlaxoSmithKline plc, which appears in this Annual Report on Form 20-F.
/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP London, England 28 February 2014 |